Clinical characteristics and chemotherapy efficacy in patients with newly diagnosed multiple myeloma:observation of 176 cases
10.3760/cma.j.issn.1009-9921.2016.09.006
- VernacularTitle:初诊多发性骨髓瘤176例临床特点及化疗效果观察
- Author:
Shunji GAO
;
Yanhua SUN
;
Hongguo ZHAO
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Clinical characteristics;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2016;25(9):539-542
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics and treatment efficacy in newly diagnosed multiple myeloma (MM). Methods The clinical data and treatment methods of 176 patients with newly diagnosed MM were retrospectively analyzed. Results The most common chief complaint in the patients with MM was bone pain. 26.1 % (46/176) patients once experienced misdiagnosis. The overall response rate (ORR) was 65.9 % (116/176), the ORR of bortezomib group (81.0 %, 34/42) was significantly higher than that of M2 regimen group (61.8 %, 34/55) and VAD regimen group (60.8 %, 48/79) (P<0.05). Between normal renal function subgroup and renal insufficiency subgroup in bortezomib group, the efficacy was no significant difference (P>0.05). The most common adverse reactions included hematologic toxicity, infection and peripheral neurotoxicity. Multiple organ failure was the main cause of death (47.1 %, 16/34). Conclusions The clinical manifestations of MM are complex and diverse, which is easy to be misdiagnosed. Molecular genetic abnormalities are closely related to prognosis. Proteasome inhibitor bortezomib can improve the curative effect and not be affected by renal function. To prolong the survival time of the patients needs to prevent and control the infection and renal insufficiency actively.
